Trial Profile
A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Satraplatin (Primary) ; Cabazitaxel; Docetaxel; Mitoxantrone
- Indications Prostate cancer
- Focus Therapeutic Use
- 03 May 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 03 May 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 19 Oct 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.